The new Alzheimer’s drug aducanumab does one thing really well…
It clears away amyloid brain plaque.
Unfortunately, clinical trials show there’s something else it doesn’t do very well at all…
It doesn’t help Alzheimer’s patients get better.
So why did the FDA grant accelerated approval, making it the first new Alzheimer’s medication to hit the market in 18 years?
Because the agency and Big Pharma refuse to let go of the long-discredited “amyloid hypothesis.”… Read More